Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
The partnership also sets the stage for broader collaboration on rare disease treatments
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
Subscribe To Our Newsletter & Stay Updated